Prevnar trial results needed for CDC recommendation

Advisors to the U.S. Centers for Disease Control and Prevention on Wednesday will wait for results from a trial of Pfizer Inc’s Prevnar 13 pneumonia vaccine before deciding whether to recommend its use in all adults aged 50 and older.

The trial results, expected next year, along with data on whether use of the vaccine in children is affecting rates of disease in adults, will be assessed before a recommendation is made, said CDC spokeswoman Alison Patti.

The Food and Drug Administration in December approved use of Prevnar 13 in older adults and Pfizer said it still expects to begin a marketing campaign in March.

- Full Story - »»»